British genomics company Genomics Ltd launched Mystra, an AI‑enabled genomics platform designed to speed target and biomarker discovery by integrating data from ~20,000 GWAS and trillions of data rows. Mystra uses machine‑learning workflows to automate evidence synthesis for candidate targets, scoring support across indications and generating indication prioritization — reportedly accessible via AWS and a web portal with self‑service and enterprise models. The company said it will demonstrate Mystra at ASHG to show how rapid genetic evidence aggregation can inform in‑licensing and preclinical prioritization for drug developers. A separate business announcement positioned the firm as a service provider to drug developers seeking scalable human‑genetics evidence.